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Abstract: The preparation, properties, and application in adriamycin delivery of biocompatible 
and biodegradable poly(lactide-co-glycolide)-polyethylene glycol (PLGA-PEG) nanoparticles 
are discussed. PLGA-PEG copolymers were synthesized by ring opening polymerization of 
the dl-lactide and glycolide in the presence of PEG1000. 1H-NMR and FT-IR spectrum were 
consistent with the structure of PLGA-PEG copolymers. The adriamycin-loaded nanoparticles 
could be prepared using a precipitation-solvent evaporation technique. The nanoparticles have 
been produced by a precipitation-solvent evaporation technique. The physical characteristics and 
drug loading efﬁ  ciency of the PLGA-PEG nanoparticles were inﬂ  uenced by the composition of 
the PLGA-PEG copolymers used to prepare the nanoparticles. Particle sizes were between 65 
and 100 nm for different compositions of PLGA-PEG copolymers. PLGA-PEG nanoparticles 
prepared from copolymers having relatively high PLGA/PEG ratios were smaller. Entrapment 
efﬁ  ciency was 25%–33%. Adriamycin release from the nanoparticles at pH 7.4 showed an 
initial burst release and then sustained release phase. These results showed that PLGA-PEG 
nanoparticles could be an effective carrier for cancer therapy.
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Introduction
The development of drug delivery systems has improved the therapeutic and 
toxicological properties of existing chemotherapies and facilitated the implementation 
of new ones. By including the drug in technologically optimized drug delivery 
systems or conjugating the drugs with different polymers, it is possible to modify the 
pharmacokinetics and biodistribution of the drugs improving the efﬁ  cacy and security 
of the therapy (Peppas and Blanchette 2004).
A critical advantage in treating cancer with advanced, non-solution based therapies 
is the inherent leaky vasculature present serving cancerous tissues. The defective 
vascular architecture, created due to the rapid vascularization necessary to serve fast-
growing cancers, coupled with poor lymphatic drainage allows an enhanced permeation 
and retention effect (EPR effect) (Teicher 2000; Sledge and Miller 2003).
Targeting the tumor vasculature is a strategy that can allow targeted delivery to 
a wide range of tumor types (Eatock et al 2000; Reynolds et al 2003).Tremendous 
opportunities exist for using nanoparticles as controlled drug delivery systems for 
cancer treatment (Panyam and Labhasetwar 2003; Birnham and Branno-Peppas 2004). 
Natural and synthetic polymers including albumin, ﬁ  brinogen, alginate, chitosan, and 
collagen have been used for the fabrication of nanoparticles. However, among all of 
these, lactic-glycolic acid copolymers are the most frequently employed materials 
due to their biocompatibility and biodegradability (Orive et al 2005). Nanoparticulate 
drug carriers must show persistence in systemic circulation after intravenous (i.v.) 
administration in order to be useful for controlled drug delivery and/or targeting International Journal of Nanomedicine 2006:1(4) 536
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applications. The biodistribution properties of polylactide-
co-glycolide-co-polyethylene glycol (PLGA-PEG) nanopar-
ticles have been studied in experimental animals after 
labeling them with radioactive agents. The results showed 
a character of extending half-life and ability to control the 
release of the encapsulated compounds (Li et al 2001). 
PLGA-PEG nanoparticles were found to exhibit linear, 
dose-independent pharmacokinetics for a dose range of 
150–1050 μg per mouse. The dosage-independence of the 
PLGA-PEG nanoparticles would provide further advantages 
for their application in controlled drug delivery and targeting 
(Beletsi et al 2005).
One of the most potent and widely used anticancer drugs 
is an adriamycin (doxorubicin), which works by inhibiting the 
synthesis of nucleic acids within cancer cells (Yoo and Park 
2000). Adriamycin has a number of undesirable side-effects 
such as cardiotoxicity and myelosupression, which leads to 
a very narrow therapeutic index. Various researchers have 
studied ways to target adriamycin delivery to cancer tissues 
or at least to diminish its side effects (Kwon et al 1995; Mitra 
et al 2001; Na et al 2003; Shikata et al 2002).
The aim of present work was to assess the merits of 
PEG-PLGA nanoparticles as an adriamycin carrier. For this 
purpose, the copolymer PLGA-PEG was synthesized and 
characterized. Polymeric nanoparticles were prepared using 
a precipitation-solvent evaporation technique. The loading 
efﬁ  ciency of the nanoparticles and in-vitro drug release from 
the nanoparticles was investigated.
Materials and methods
Materials
DL-Lactide (LA) and glycolide (GA) were purchased from 
Boehringer Ingelheim (Germany). They were recrystallized 
twice from ethyl acetate and dried under high vacuum at 
room temperature before use. Polyethylene glycol (PEG, 
molecular weight: 1000) was obtained from Sigma Chemical 
Co. (St. Louis, MO, USA) and dried under high vacuum 
at room temperature. Stannous octoate was also obtained 
from Sigma.
Synthesis and characterization 
of PLGA-PEG copolymers
PLGA-PEG copolymers of different composition were 
prepared by a melt polymerization process under nitrogen, 
using stannous octoate as catalyst (Beletsi et al 1999). They 
were characterized by FT-IR (Shimadzu 8400) and 1H-NMR 
(Bruker AC-80) and their molecular weight and molecular 
weight distribution (polydispersity index, Mw/Mn) was 
determinedly gel permeation chromatography (GPC, Walters, 
515 HPMC pump).
Preparation of nanoparticles
PLGA-PEG nanoparticles were prepared using a precipitation-
solvent evaporation technique (Avgoustakis et al 2003). 
Brieﬂ  y, a solution of the polymer in acetone was transferred 
drop wise to a stirred aqueous solution of poly vinyl alcohol 
(PVA, molecular weight: 10000, 0.5% w/v). The mixture 
was kept under stirring until acetone had been evaporated, 
and the nanoparticle dispersion formed was condensed in a 
rotary evaporator and ﬁ  ltered through a 1.2 μm ﬁ  lter (Millex 
AP, Millipore). Finally, the nanoparticles were collected by 
centrifugation at 25000×g for 25 min and washed twice with 
water before lyophilization (Christ Alpha 1–4).
FT-IR (cm−1): 3010, 2955, 2880, 1765, 1185-1070.
H-NMR (ppm); δ=3.7 (m, 4H, methylene groups of 
PEG), δ=1.6 (d, 3H, methyl group of the lactide), δ=4.8 
(d, 2H, methylene group of glycolide), δ=5.2 (m, 1H, CH 
of lactide).
Observation of transmission electron 
microscope (TEM)
The morphology of the polymeric nanoparticles was observed 
using a TEM (LEO 960). A drop of drug loaded nanoparticle 
suspension in aqueous solution was placed on a carbon ﬁ  lm 
coated on a copper grid for TEM and freez-dried. Observa-
tion was done at 80 kV.
Entrapment efﬁ  ciency
Loaded drug quantity was determined according to the 
following procedure: after nanoparticles were formed, 
unbound adriamycin was separated by centrifugation at 
30000×g at 25º C for 10 min and the precipitate was dis-
carded. The precipitate was then lyophilized and resulting 
powder containing the loaded nanoparticles was dissolved 
in ethanol to obtain a clear solution and analyzed UV spec-
trophotometrically (Shimadzu UV-160) at 479 nm. Loading 
capacity was expressed in terms of entrapped drug quantity, 
and entrapment efﬁ  ciency.
In vitro drug release
The in vitro release experiments were carried out as 
follows: 5g of adriamycin-loaded polymeric nanoparticles 
and 1 ml of phosphate buffer saline (PBS 0.1 M, pH 7.4) 
were put into a dialysis tube and then was introduced into 
a vial with 10 mL of PBS. At speciﬁ  c time interval, the International Journal of Nanomedicine 2006:1(4) 537
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whole medium was taken and replaced with fresh PBS. The 
concentration of the released adriamycin was determined by 
UV spectrophotometer at 479 nm.
Results and discussion
Synthesis and characterization 
of PLGA-PEG copolymers
PLGA-PEG copolymers of different composition were 
prepared by a melt polymerization process. They were char-
acterized with regard to their composition by 1H-NMR and 
their molecular weight and molecular weight distribution 
The results are given in Table 1.
It was found that drug loading contents and loading efﬁ  -
ciency increased with a decrease of PEG percent in the 
copolymer.
Total release of adriamycin from PLGA-PEG nanopar-
ticles is shown in Figure 2.
These results indicate that the release of adriamycin 
from the nanoparticles decreased with an increase of PEG 
content in PLGA-PEG nanoparticles. The slower release in 
the nanoparticles with higher PEG content can be attributed 
to the stronger hydrophobic interaction between hydrophobic 
domain (PLGA) and drug. It was also found that the greater 
the drug content, the slower the drug release.
In the release pattern of the samples a pseudo zero-order 
release after an initial burst release effect was observed. It is 
generally assumed that a drug is released by several processes 
such as diffusion through the polymer matrix, release by 
Table 1 Characterization of PLGA-PEG copolymers of with 
different composition
Mw/Mn Mw Yield 
(%)
LA/GA/PEG 
(Mole %)
Sample
3.51 11200 71 57:18:25 PI
3.1 10800 64 45:15:40 PII
3.3 8400 54 30:10:60 PIII
Table 2 Physicochemical characteristics and encapsulation 
efﬁ  ciency of adriamycin-loaded PLGA-PEG nanoparticles*
Mean 
diameter 
(nm)
Drug
loading
%
Loading 
efﬁ  ciency
Entrapped
drug quantity
(μg/mL)
Sample
65±11.4 22.5±5.7 33±2.5 161±8.8 PI
78±13.7 19.4±4.5 29±8 155±11.2 PII
94±15.8 17.8±3.4 25±3.6 143±6.5 PIII
mean±SD (n=3)*
Physicochemical characterization 
of nanoparticles
In order to investigate the physicochemical characteristics 
of nanoparticles, they were observed by TEM (Figure 1). 
From these micrographs, nanoparticles prepared with PLGA-
PEG were spherical in shape and uniform with size about 
60–100 nm.
The encapsulation efﬁ  ciency values achieved for adria-
mycin were inﬂ  uenced by the presence of PEG in PLGA-PEG 
chains (Table 2).
From the values in Table 2, the particle sizes were depen-
dent on the PEG percent of the copolymer i.e., the higher the 
PEG percent, the larger the particle size.
Drug loading and release study in vitro
The adriamycin loading contents and loading efﬁ  ciency 
onto the PLGA-PEG nanoparticles are shown in Table 2. 
Figure 1 Transmission electron microscopy (TEM) photographs of adriamycin-loaded 
PLGA-PEG nanoparticles (A: sample PI, B: sample PII, C: sample PIII ).International Journal of Nanomedicine 2006:1(4) 538
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polymer degradation and solubilization and diffusion through 
microchannels that exist in the polymer matrix or are formed 
by erosion (Jeong et al 1999).In this system, polymer 
degradation occurred after about 21–25 days; accordingly, we 
can consider that the drug is released from the nanoparticles 
through the diffusion mechanism in vitro.
The measured acidic pH of extracellular ﬂ  uid of solid 
tumors has extensively been documented for a few decades, 
combined with biological backgrounds of this observation. 
The acidic pH is now regarded as a phenotype of solid tumors 
for their growth and invasiveness (Tannock and Rotin 1989; 
Stubbs et al 2000). This ﬁ  nding has prompted investigators 
to fabricate pH-sensitive carriers by decorating the surface 
with carboxylic groups. Based on their ﬁ  ndings, at pH 6.8 
and 6.4 the pH-sensitive nanoparticles aggressively bounded 
to tumor cells.
The adriamycin release rate from the PLGA-PEG 
nanoparticles was also pH-dependent and enhanced at pH 6.4, 
as presented in Figure 3.It is generally assumed that a drug is 
released by several process (Gref et al 1994) such as diffusion 
through the polymer matrix, release by polymer degradation 
and solubilization and diffusion through microchannels that 
exist in the polymer matrix or are formed by erosion. The 
copolymers prepared in the present work are ABA triblock 
copolymers composed of hydrophobic A-blocks (lactide-co-
glycolide) and hydrophilic B blocks (central PEG). These 
copolymers are not soluble in   water but exhibit reverse 
thermal and pH-dependent gelation properties. Hydrolysis 
of the ester linkage in these polymers will cause the swelling 
to increase with time as hydrolysis proceeds. The gel 
becomes increasingly pH-sensitive as hydrolysis proceeds 
and carboxylic acid groups are generated in the structure. 
In within a few days (6 days) we can consider that the drug 
is released from the PLGA-PEG nanoparticles through the 
diffusion mechanism in vitro. The swelling of the particles 
increased in acidic buffered solutions due to the protonation 
of PEG central groups and formation of positively charged 
chains in the polymer structure.
Conclusion
To reduce or minimize undesired interactions or undesired 
uptake into normal sites, a biodegradable nanocarrier has 
been developed for adriamycin wherein the amount and 
site of drug release is controlled by the structure of the 
copolymer and pH. This nanoparticle was designed and 
prepared, so that the carrier can be used for targeting a 
broad range of solid tumors. For this purpose, ABA triblock 
copolymers of PLGA-PEG were synthesized by ring 
opening polymerization of the lactide and glycolide in the 
presence of PEG 1000. 1H-NMR and FT-IR spectrum were 
consistent with the structure of PLGA-PEG copolymer. The 
adriamycin-loaded nanoparticles could be prepared using 
a precipitation-solvent evaporation technique. The entrap-
ment efﬁ  ciency was 25%–33%, and particle size about 
65–95 nm. Adriamycin release from the nanoparticles at 
pH 7.4 showed an initial burst release and then sustained 
release phase.
The results demonstrated in-vitro that the adriamycin 
loaded PLGA-PEG nanoparticles show pH sensitivity and 
can be applied for targeting extracellular pH (pHc) and could 
be an effective carrier for cancer therapy. It is expected that 
at tumor pH the adriamycin loaded nanoparticles made of 
PLGA-PEG triblock copolymers can show enhanced cyto-
toxicity compared to that at normal pH.
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Figure 2 Release of adriamycin (ADR) from PLGA-PEG nanoparticles at pH 7.4, 
37ºC (average ±SD, n=3).
Figure 3 pH-dependent adriamycin (ADR) release from PI (25% PEG) at 37ºC 
(average ±SD, n=3).International Journal of Nanomedicine 2006:1(4) 539
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